Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel

被引:21
作者
Fiorella, David [1 ]
机构
[1] SUNY Stony Brook, Dept Neurosurg, Cerebrovasc Ctr, Med Ctr, Stony Brook, NY 11794 USA
关键词
PERCUTANEOUS CORONARY INTERVENTION; LOW-DOSE ASPIRIN; PLATELET REACTIVITY; DOUBLE-BLIND; CARDIOVASCULAR-DISEASE; ANTIPLATELET THERAPY; STENT IMPLANTATION; NONCARDIAC SURGERY; RESISTANCE; RESPONSIVENESS;
D O I
10.1136/jnis.2009.001859
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
The majority of neurological complications encountered during neuroendovascular procedures are a result of thromboembolic phenomena. This has become increasingly evident as techniques have evolved to incorporate an ever-growing volume of temporary and permanently implanted adjunctive devices. By optimizing our anti-thrombotic management strategies we can potentially improve procedural safety. The appropriate selection of anti-thrombotic regimens for neurointerventional procedures poses a unique set of challenges when compared with endovascular interventions in other vascular territories. Neurological procedures frequently target lesions that have hemorrhaged or have a lethal hemorrhagic potentiald-thus requiring that the operator maintain a tenuous balance between bleeding and thrombosis. Neurological end-organs are unforgiving, even of small emboli, further magnifying the implications of inadequate therapy. The spectrum of disease processes encountered within the context of routine clinical practice is very heterogeneous and each lesion requires a specific anti-thrombotic strategy. The diseases treated (eg, aneurysms, AVM, acute ischemic stroke, chronic atherosclerotic stenosis) are relatively uncommon in comparison with coronary or peripheral atherosclerotic disease. The field of neurointervention itself is still relatively new and continues to evolve rapidly, with innovation frequently outpacing clinical evidence. Predictably, within this environment, there are no large, controlled trials to guide anti-thrombotic management in most cases. For these reasons, medical decision making is based largely upon an understanding of the pharmacology of the agents used and an extrapolation of the literature from other fields. In this review we discuss aspirin and clopidogrel, the two anti-platelet agents commonly used in conjunction with endovascular stents and stent-like devices. We will discuss their pharmacology and applications in neuroendovascular therapeutics with a focus on practical solutions to dilemmas that are encountered during the course of daily clinical practice.
引用
收藏
页码:44 / 49
页数:6
相关论文
共 63 条
[1]   Antiplatelet effect of aspirin in patients with cerebrovascular disease [J].
Alberts, MJ ;
Bergman, DL ;
Molner, E ;
Jovanovic, BD ;
Ushiwata, I ;
Teruya, J .
STROKE, 2004, 35 (01) :175-178
[2]   Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention Results From the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study [J].
Aleil, Boris ;
Jacquemin, Laurent ;
De Poli, Fabien ;
Zaehringer, Michel ;
Collet, Jean-Philippe ;
Montalescot, Gilles ;
Cazenave, Jean-Pierre ;
Dickele, Marie-Claude ;
Monassier, Jean-Pierre ;
Gachet, Christian .
JACC-CARDIOVASCULAR INTERVENTIONS, 2008, 1 (06) :631-638
[3]   Variability in individual responsiveness to clopidogrel - Clinical implications, management, and future perspectives [J].
Angiolillo, Dominick J. ;
Fernandez-Ortiz, Antonio ;
Bernardo, Esther ;
Alfonso, Fernando ;
Macaya, Carlos ;
Bass, Theodore A. ;
Costa, Marco A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (14) :1505-1516
[4]   Loading, pretreatment, and interindividual variability issues with clopidogrel dosing [J].
Bates, ER ;
Lau, WC ;
Bleske, BE .
CIRCULATION, 2005, 111 (20) :2557-2559
[5]   Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) [J].
Bertrand, ME ;
Rupprecht, HJ ;
Urban, P ;
Gershlick, AH .
CIRCULATION, 2000, 102 (06) :624-629
[6]   Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].
Bhatt, DL ;
Fox, KAA ;
Hacke, W ;
Berger, PB ;
Black, HR ;
Boden, WE ;
Cacoub, P ;
Cohen, EA ;
Creager, MA ;
Easton, JD ;
Flather, MD ;
Haffner, SM ;
Hamm, CW ;
Hankey, GJ ;
Johnston, SC ;
Mak, KH ;
Mas, JL ;
Montalescot, G ;
Pearson, TA ;
Steg, PG ;
Steinhubl, SR ;
Weber, MA ;
Brennan, DM ;
Fabry-Ribaudo, L ;
Booth, J ;
Topol, EJ ;
Frye, RL ;
Amarenco, P ;
Brass, LM ;
Buyse, M ;
Cohen, LS ;
DeMets, DL ;
Fuster, V ;
Hart, RG ;
Marler, JR ;
McCarthy, C ;
Schoemig, A ;
Lincoff, AM ;
Brener, SJ ;
Sila, CA ;
Albuquerque, A ;
Aroutiounov, G ;
Artemiev, D ;
Atkeson, BG ;
Bartel, T ;
Basart, DCG ;
Lima, AB ;
Belli, G ;
Bordalo e Sa, AL ;
Bosch, X .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717
[7]  
BHATT DL, 2009, TRANSCATHETER CADIOV
[8]   Benefits of clopiclogrel in patients undergoing coronary stenting significantly depend on loading dose: Evidence from a meta-regression [J].
Biondi-Zoccai, Giuseppe G. L. ;
Lotrionte, Marzia ;
Agostoni, Pierfrancesco ;
Valgimigli, Marco ;
Abbate, Antonio ;
Sangiorgi, Giuseppe ;
Moretti, Claudio ;
Sheiban, Imad .
AMERICAN HEART JOURNAL, 2007, 153 (04) :587-593
[9]   A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans [J].
Bossavy, JP ;
Thalamas, C ;
Sagnard, L ;
Barret, A ;
Sakariassen, K ;
Boneu, B ;
Cadroy, Y .
BLOOD, 1998, 92 (05) :1518-1525
[10]   Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. [J].
Catella-Lawson, F ;
Reilly, MP ;
Kapoor, SC ;
Cucchiara, AJ ;
DeMarco, S ;
Tournier, B ;
Vyas, SN ;
FitzGerald, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) :1809-1817